Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ: LENZ )

23.97 -0.10 (-0.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 62,918
Open 24.46
Bid (Size) 23.88 (1)
Ask (Size) 23.98 (2)
Prev. Close 24.07
Today's Range 23.61 - 24.84
52wk Range 14.42 - 24.59
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga

Performance

YTD
+47.96%
+47.96%
1 Month
+35.50%
+35.50%
3 Month
+55.15%
+55.15%
6 Month
+47.96%
+47.96%
1 Year
+47.96%
+47.96%

More News

Read More
ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday
Via Benzinga
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
From Lenz Therapeutics, Inc.
Via GlobeNewswire
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says
Via Benzinga
Newly Listed Lenz Therapeutics' Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study
Via Benzinga
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
From LENZ Therapeutics, Inc.
Via Business Wire
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
From LENZ Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.